Mukul Agarwal bets on women's healthcare via Gaudium IVF
India's organised fertility-care market is still tiny and fragmented — which is partly why Mukul Agarwal's March-2026-quarter bet on Gaudium IVF and Women Health Ltd was a sizeable stake by value for that quarter.
CMP ₹116 (screener.in, close of 18 September 2026 — the most recent trading session; 20 September is a non-trading Sunday, so this is the latest available close, not a live intraday price) · Market cap ₹846 crore · P/E 39.2x (trailing) — there's still no directly comparable pure-play IVF chain listed in India, so treat the multiple on its own terms rather than against a benchmark. The closest potential peer, Indira IVF Hospital (the market leader, backed by EQT), has SEBI approval (granted 30 December 2025) to launch its own IPO but has not announced dates or listed as of this writing — worth revisiting once that actually happens.
What Gaudium IVF actually does — and its listing details
Incorporated in March 2015. Gaudium runs a hub-and-spoke chain of IVF and women's-health clinics — 8 hubs and 28 spokes as of Q1 FY27, including international referral spokes in Paris, Nigeria and Sydney that bring in medical-tourism patients (an IVF cycle in India costs roughly a fifth of the US price). It competes in a market dominated by large private chains (Indira IVF, Nova IVF and others) that mostly aren't independently listed. It's a mainboard-listed company, with its IPO priced at ₹75-79/share, opening February 20-24, 2026 and listing on February 27, 2026, raising ₹165 crore (₹90 crore fresh issue, the balance an offer-for-sale).
FY26 (year to March 2026) consolidated results grew strongly across the board, though growth cooled sharply in the first quarter of the new financial year:
Metric FY26 (full year) YoY growth --------- Revenue ₹104.35 crore +47.6% EBITDA ₹37.70 crore +31.7% PAT ₹24.48 crore +27.7%
Q1 FY27 (the quarter management itself called "a quarter of quiet, deliberate progress") looked much weaker on the surface:
Metric Q1 FY27 YoY change --------- Revenue ₹19.4 crore +9.1% EBITDA ₹2.4 crore (margin 12.5%, down from 29%) -52.96% PAT ₹1.8 crore (from ₹3.1 crore) -42.27%
But management's own numbers show this is mostly a timing effect, not a business slowdown: excluding one-off costs — pre-operational spend on the new South Extension (Delhi) hub, preparatory costs for upcoming centres, and a one-time pan-India marketing push for its two new AI tools — adjusted EBITDA margin would have been roughly 27.6%, close to FY26's underlying run-rate. Revenue growth was also held back by a seasonal effect the company flagged directly: Q1 (April-June) is structurally weak because extreme North Indian heat suppresses patient visits.
A reported number and an "adjusted" number can tell very different stories — check which one you're reading A 52.96% EBITDA decline sounds alarming on its own. Management's own explanation — front-loaded hub-opening and marketing costs, concentrated in one quarter — brings the adjusted margin back to roughly 27.6%, near FY26 levels. Both framings are real: the reported number is what actually happened this quarter; the adjusted number is management's case for why it doesn't represent the ongoing business. Reading only one of the two gives an incomplete picture.
Mukul Agarwal's stake
Mukul Agarwal took a 3.43% stake for approximately ₹29 crore in the March 2026 quarter — a sizeable stake by rupee value, in a women's-healthcare business he specifically flagged for its tier-2/tier-3 city expansion potential. As with his other new positions that quarter, this came through a quarterly shareholding disclosure, which reports the resulting stake and its approximate value but not the exact per-share price paid over the quarter.
Management's own guidance
On the Q1 FY27 call, management explicitly confirmed a 30% revenue growth target for FY27 (stated directly in response to an analyst question: "Yes, right") and committed to bringing EBITDA and PAT back to adjusted-FY26 levels by year-end. The FY27 hub rollout, as laid out on that call, was running well behind schedule:
Hub(s) Count Status (as of the Q1 FY27 call) --------- South Extension (Delhi) 1 Commissioned mid-July 2026 Gurgaon, Nagpur 2 Expected within weeks Remaining hubs 7 Targeted by March 2027
Only 1 of the 10 new IVF hubs planned for FY27 was commissioned as of the call date — real execution risk if the rollout slips. Separately, an analyst pressed management on its own regulatory-consolidation narrative (the ART & Surrogacy Act pushing India's 70% unorganised IVF market toward listed/organised players): management conceded state-level implementation is "patchy" and will likely take "another year or so" — a real tempering of a thesis point management itself had led with.
Should you chase it?
Gaudium's FY26 growth is genuinely strong, and it was Mukul Agarwal's second-largest fresh bet that quarter — a real, if not top, signal of conviction. The Q1 FY27 headline decline looks worse than the underlying, adjusted picture suggests, and management has now put an explicit 30% FY27 growth number behind its own guidance. But there's still no clean listed peer to sanity-check the ~39x multiple against (Indira IVF remains unlisted despite its SEBI approval), the FY27 plan depends on commissioning nine more hubs on schedule (only one was done as of the last call), and management's own regulatory-tailwind thesis has been pushed out by roughly a year. Read the Q1 FY27 results, the hub-commissioning pace, and the adjusted-vs-reported margin gap directly before treating Agarwal's stake here as a reason to follow in.
Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.
Sources
- Gaudium IVF and Women Health — screener.in - Gaudium IVF and Women Health — screener.in consolidated financials - Gaudium IVF Q1 FY27 earnings-call transcript (NSE filing) - Indira IVF Hospital IPO status — Chittorgarh